Canopy(1) | $22,000,000 | (Jan 13, 2026)
Onsetto | $2,200,000 | (Jan 13, 2026)
BlueNalu | $11,000,000 | (Jan 13, 2026)
Diagonal Therapeutics
United States
- Watertown, Massachusetts
- 13/01/2026
- Series B
- $125,000,000
Diagonal Therapeutics is developing a new class of clustering antibody medicines designed to address the root causes of severe genetic diseases. Using our DIAGONAL platform, we engineer clustering bispecific antibodies to restore healthy cell signaling in genetically driven diseases. This innovative approach offers potential therapies that can modify disease biology, providing lasting benefits for patients with limited treatment options.
Our lead program, DIAG723, targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), two serious vascular diseases with significant unmet needs. It focuses on the dysregulated signaling that contributes to both conditions, showing promising results in early models.
With strong investor support and a growing clinical pipeline, Diagonal Therapeutics is redefining treatment possibilities for challenging genetic diseases, moving beyond symptom relief to disease modification.
Learn more at: www.diagonaltx.com
- Industry Biotechnology
- Website https://diagonaltx.com/
- LinkedIn https://www.linkedin.com/company/diagonal-therapeutics/
Related People
Alexey "Alex" LugovskoyFounder
United States -
Cambridge, Massachusetts
25 years in drug discovery and development, guiding biologics and small molecule programs from inception to clinical proof of concept. Proven ability to integrate biology, technology, clinical, regulatory, and business insights to build company value and deliver new medicines to patients. Experience in raising capital through private and public financings and strategic collaborations. An innovator with 100+ patents and peer-reviewed publications. Co-inventor of tovorafenib (Ojemda™), an therapy for children 6 months or older living with pediatric low-grade glioma. Collaborator and mentor, who inspires teams to reach their full potential.
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
Kinaset Therapeutics | $103,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)
encoord | $2,000,000 | (Jan 13, 2026)
Vibrant Therapeutics | $61,000,000 | (Jan 13, 2026)
Avenue Biosciences | $7,500,000 | (Jan 13, 2026)
Unusual | $3,600,000 | (Jan 13, 2026)